Hoxsey herbal treatment

1. What it was

Version followed: the Hoxsey regimen as described in the 1952 Fifth Circuit judgment against the Dallas Hoxsey Cancer Clinic, the Memorial Sloan Kettering (MSK) "About Herbs" monograph (updated 2021), FDA consumer material, and the 2001 outcomes feasibility study that included the Bio-Medical Center in Tijuana. This is a historical account written so that clinicians can recognise the regimen and its descendants. It is not a treatment and has no legitimate implementation for a psychotherapist. Nothing here describes it as a treatment for cancer or any other disease.

Who, where, when.

Harry M. Hoxsey was a layman with no medical training who sold cancer "cures" for more than three decades and earned millions [source: FDA, Products Claiming to "Cure" Cancer]. The 1952 court called him "a layman" who ran the preparation and distribution of the medicines at the Hoxsey Cancer Clinic in Dallas, Texas [source: US v. Hoxsey Cancer Clinic, 198 F.2d 273].
He ran a chain of clinics. Sources name West Virginia, Michigan, New Jersey and Texas [source: McGill OSS, Schwarcz 2017]. MSK records that he was convicted many times for practising medicine without a licence [source: MSK].
Osteopathic physicians took part. The clinic's medical director in Dallas was an osteopath, and osteopaths elsewhere received the liquid medicine in concentrated form by interstate shipment [source: 198 F.2d 273].
The FDA warned the public about the treatment in 1956 [source: Science Feedback 2022]. In 1957 it placed a warning poster in post offices across the US, and it helped remove the products from the market in the 1950s [source: FDA]. One account says the government had put Hoxsey out of business by 1960 [source: McGill OSS]. The exact date and form of the final US shutdown is [uncertain: not verified].
The regimen then moved to clinics in Tijuana, Mexico, where it has been offered although it is illegal in the US [source: MSK]. One of these was the Bio-Medical Center in Tijuana [source: Richardson et al. 2001]. The year the Tijuana clinic opened and the identity of the nurse often said to have run it are [uncertain: not verified]. MSK quotes Hoxsey's "head nurse" on the claimed mechanism without naming her [source: MSK].

Stated rationale.

Origin story: Hoxsey's own 1956 autobiography, You Don't Have to Die, says a great-grandfather's horse recovered from a growth on its leg after grazing on wild plants, and that the plants were made into cancer remedies passed down the family [source: McGill OSS; MSK]. MSK adds that Hoxsey combined these plants with home cancer remedies popular at the time [source: MSK].
Claimed mechanism: the internal tonic was said to eliminate "toxins", correct blood chemistry and normalise cell metabolism. Later, his head nurse said it restored acid–base balance and immune function and "deals with the DNA" [source: MSK]. Proponents also claimed the tonic detoxified the body, strengthened immunity and let the body "digest and excrete" tumours. Hoxsey said the topical medicine killed only cancer cells [source: MSK]. MSK states that none of these claims is supported by scientific data.

How it was sold.

To patients: through a booklet. It listed named patients with the sites of their cancers, reprinted their testimony, showed "before and after" photographs, and invited readers to write to these patients for "first-hand testimony". The booklet contained a disclaimer that the treatment was not a cure-all. The court found that it still led readers to believe they had an excellent chance of benefit and that the listed patients had been cured [source: 198 F.2d 273].
Through a persona: Hoxsey presented himself as a self-made man persecuted by the medical establishment. He said doctors performed needless surgery and radiation, and he blamed vaccines, food preservatives and fluoride. His rhetoric also included antisemitic and anticommunist themes. He claimed thousands of cures, citing as proof that his clinic drew dozens of new patients a day for thirty years [source: McGill OSS].
To referrers: through a network of osteopaths who received and dispensed the medicine [source: 198 F.2d 273]. Hoxsey also repeatedly challenged the AMA to investigate. When patient files were handed over, they lacked the histories and examination records needed to evaluate them [source: McGill OSS].
Price: in one documented offer, the treatment package plus a six-week stay at his hospital was a large sum for the time [source: McGill OSS].

2. What was actually done

The sequence below combines the court record (Dallas, early 1950s), MSK's monograph, and the Tijuana records study (1992 patients). Where a step is inferred from these, it is marked.

Arrival and selection. People came directly, by referral from an osteopath in the network, or after reading the testimonial booklet [source: 198 F.2d 273]. In the Tijuana sample, most new patients were US residents, married, average age early 50s, within a year of diagnosis of breast, colorectal, lung or male genital cancer. Most arrived with regional or distant disease after surgery, chemotherapy or radiotherapy [source: Richardson et al. 2001]. Nobody was screened out because they did not have cancer. Only about 54% of the clinic's new patients were treated for cancer at all, and fewer than half of those cases had pathological confirmation [source: Richardson et al. 2001].
"Diagnosis". Hoxsey or his staff made the diagnosis [source: McGill OSS]. The Dallas medical director testified that he did not need a biopsy to diagnose cancer. The court noted that he diagnosed cancer in one person within 15 days of a negative biopsy, without doing a new one [source: 198 F.2d 273]. People who had never had cancer were labelled as having it and later counted as cures. Documented examples include a man whose "cancer" was later found to be a skin infection ("barber's itch"). An FDA undercover agent was told he had advanced prostate cancer spreading to the lungs, and was then told it had been "arrested in time" [source: McGill OSS]. Hoxsey argued that anyone who needed a biopsy lacked experience [source: McGill OSS].
Consent and pressure. No source describes an informed-consent process. The conditions for consent were undermined by the false diagnoses, the booklet's implied promise, the persecution story that cast doctors as the enemy, and the package price paid up front [source: 198 F.2d 273; McGill OSS]. The description of these as consent pressures is [synthesis].
Internal medicine. Patients were given a dark liquid tonic (the court calls it the "black" or brownish-black medicine) to take at home. It was a concentrate of potassium iodide and extracts of several barks and herbs, dispensed already diluted to patients and concentrated to osteopaths. A second, "pink" liquid contained potassium iodide and pepsin [source: 198 F.2d 273]. MSK lists the tonic's components as potassium iodide, licorice, red clover, burdock root, stillingia root, barberry, cascara, pokeweed, prickly ash bark and buckthorn bark [source: MSK]. Supplies were shipped across state lines for continued use at home. One shipment went out days before trial [source: 198 F.2d 273].
External preparations for visible or skin tumours. The clinic sold a powder and a salve. The court described them as escharotics (corrosive agents) with arsenic as their base. Testimony said they destroyed normal tissue as well as cancer tissue [source: 198 F.2d 273]. MSK describes caustic ingredients that burn healthy tissue and cause severe burns, scars and disfigurement [source: MSK]. Their use was in practice a chemical burning away of tissue on the skin, done without pathology, without margins and without anaesthetic standards [synthesis from these sources].
Diet and add-ons. Patients followed a restrictive diet. It banned pork, vinegar, tomatoes, pickles, carbonated drinks, alcohol, bleached flour, sugar and salt, and stressed iron, calcium, vitamin C, yeast supplements and grape juice [source: MSK]. Later regimens sometimes added other products: superoxide dismutase, vitamin B12, a procaine-based "rejuvenation" product, liver extract, cactus preparations, "antitoxins", BCG vaccine and other proprietary items [source: MSK].
Judging "progress". Progress was judged by the clinic's own unbiopsied assessments, by patients' and families' beliefs that they were improving or cured, and by testimonials collected for the booklet [source: 198 F.2d 273]. The court held that a layperson's belief that he had had cancer, or had been cured, deserved little or no weight [source: 198 F.2d 273]. Follow-up records were so poor that later researchers could not run studies [source: MSK; Richardson et al. 2001].
Non-response, refusal and criticism. Among the government's 16 case histories, nine were patients named in the booklet. In those, biopsy showed either that the cancer had not been halted or that no cancer had existed. Some of these patients turned to surgery, and some died while on the medicine [source: 198 F.2d 273]. When such failures and outside criticism came up, the answer was the persecution narrative. Hoxsey also said the AMA had falsified his father's death certificate [source: McGill OSS]. How individual non-responders were counselled at the clinic is [uncertain: not verified].

3. How it caused harm

Delay or abandonment of effective cancer treatment. This was the main harm. In the court record, one patient declined surgery, took the medicine and died of cancer. Another regressed on the medicine and then improved with x-ray therapy [source: 198 F.2d 273]. The government reviewed about 400 people Hoxsey said he had cured. They had either never had cancer, been cured beforehand by standard treatment, still had cancer, or died of it [source: MSK; Science Feedback]. The National Cancer Institute examined 77 case reports Hoxsey submitted and found none that showed efficacy [source: MSK]. A wider modern analysis gives the scale of this mechanism: people with curable cancers who used only alternative medicine had about 2.5 times the risk of death of matched conventionally treated patients [source: Johnson et al. 2018]. That analysis did not study Hoxsey specifically.
Chemical burns and disfigurement from the escharotic paste and powder. These were arsenic-based corrosives that destroyed healthy tissue along with any tumour, causing severe burns, scarring and disfigurement [source: 198 F.2d 273; MSK]. Anyone treating a skin lesion this way also lost an accurate diagnosis and clear margins [synthesis].
Toxicity of tonic components [source: MSK]:
- Potassium iodide: "iodism", with acne-like eruptions, eye and nasal discharge, impotence and salivary-gland inflammation; it interacts with lithium (hyperthyroidism) and anticoagulants (reduced effect).
- Pokeweed: vomiting, diarrhoea and cramps. Ingestion has led to hospitalisation, heart block and deaths in children.
- Licorice: hypertension, low potassium, sodium retention and cardiac arrhythmia.
- Buckthorn and cascara: harsh laxatives, causing dehydration, fluid and electrolyte disturbance, and deficiency states with long use.
- The court also heard expert evidence that potassium iodide caused adverse reactions in many people. A pathologist testified that potassium might speed cancer growth. Laboratory mice with cancer showed no benefit from either medicine [source: 198 F.2d 273].
False diagnosis and iatrogenic illness identity. People told they had cancer when they did not lived with that belief and its fear, paid for treatment, and became testimonials. This misled others in turn [source: McGill OSS; 198 F.2d 273]. The psychological sequelae (health anxiety, an identity as a "survivor" built on a false diagnosis, later disillusionment) are inferred, not documented in the cited sources [synthesis].
Financial harm. Package fees, residential stays and continuing shipments of medicine were paid out of pocket [source: McGill OSS; 198 F.2d 273]. Later, there was travel to Mexico [source: MSK; Richardson et al. 2001].
Documented outcomes at the Tijuana clinic. In the 1992 cohort, five-year status could be determined for only 57% of cancer patients. Of all patients, 11.4% were known to be alive and 45.6% had died [source: Richardson et al. 2001]. A popular account of a 1999 federal review of the same clinic gives 17 survivors among 85 traced patients [source: McGill OSS]. The percentage it quotes does not match its own figures, so treat it as [uncertain].
Children. A five-year-old whose case was promoted to a US state legislature in 1958 died of cancer eight months after Hoxsey treatment [source: McGill OSS]. The child is not named here. Pokeweed poisoning is documented in children [source: MSK].
Who was most at risk. People with early, curable cancers who were persuaded to forgo surgery or radiotherapy; people with visible skin lesions given the escharotics; people with advanced disease who had little time and money and were looking for hope (the Tijuana sample); people on lithium or anticoagulants, or with heart or kidney problems that make licorice and laxatives dangerous; and children [source: MSK; Richardson et al. 2001; 198 F.2d 273; risk ranking is synthesis].

4. Recognising it today

Names and forms it appears under. These include "Hoxsey tonic", "Hoxsey formula", "Hoxsey method" and "Hoxsey-type" or "Hoxsey-style" herbal blends sold online. There are also "red clover combination" or "anti-tumour" tinctures listing the same plants, Mexican border clinics, and documentaries and books retelling the suppressed-cure story [source: MSK; Science Feedback; synthesis for product naming]. The OTA's 1990 report on unconventional cancer treatments covers Hoxsey and lists a related title, "Hoxsey: Quacks Who Cure Cancer?" [source: OTA report index, Quackwatch copy]. Its full content is [uncertain: not verified]. In December 2022, a social-media video retold Hoxsey as a cure suppressed by medical organisations, and fact-checkers rated the claim unsupported [source: Science Feedback].

Phrases and rationales.

"Natural cure", "treats all cancers", "non-toxic", "avoid chemotherapy or surgery", "selectively kills cancer cells" and "leaves healthy cells intact". The FDA lists these as red flags of fraudulent cancer products [source: FDA Q&A; FDA consumer update]. The last two echo Hoxsey's own claim about his topical medicine [source: MSK].
"Detoxify", "rebalance body chemistry", "restore acid–base balance", "let the body digest the tumour" [source: MSK].
"They shut him down because it worked"; doctors as profiteers; vaccines, fluoride and preservatives as causes of cancer [source: McGill OSS; Science Feedback].
Testimonials with "before and after" photographs, especially of skin lesions. Offers to put you in touch with "cured" patients [source: 198 F.2d 273; FDA Q&A].

Components still in circulation.

Black salve and other escharotic pastes for skin lesions. These descend from the same caustic approach. The specific product lineage is [uncertain: not verified]. The court's description of arsenic-based corrosive powders and salves is the historical template [source: 198 F.2d 273]. Treat any "drawing salve" applied to a suspected skin cancer as an emergency referral to a doctor [synthesis].
The individual herbs (red clover, burdock, licorice, pokeweed and others), sold as "blood purifiers". Laboratory findings on isolated plant chemicals are cited as if they were evidence of clinical benefit [source: Science Feedback; MSK].

Red flags in a colleague's or service's practice [synthesis unless cited].

Diagnosing or "confirming" cancer, or cancer remission, without pathology [source for the principle: 198 F.2d 273].
Advising against biopsy, surgery, radiotherapy or chemotherapy, or framing oncologists as adversaries.
Selling or recommending a herbal "protocol" for cancer, or receiving referral fees from a clinic.
Packaged fees paid in advance, travel to an overseas clinic, mail-order supplies.
Collecting client testimonials or case stories for promotion.
Counselling that treats doubt about the regimen as "negativity" that blocks healing.

How legitimate practice differs.

Integrative oncology (see 172) uses selected complementary therapies alongside standard care, never instead of it. It is coordinated with the oncology team and uses no caustic or "tumour-dissolving" agents [synthesis; see 172 for society sources].
Psycho-oncology addresses fear, meaning and decisions. It does not change the cancer treatment plan.
Dermatological treatment of skin cancer starts with a biopsy and is done by licensed clinicians with margin control [synthesis].
Respect for a patient's right to decline treatment is legitimate. Steering a patient towards refusal with false information is not [synthesis].

5. What to do instead and how to help those harmed

Current alternatives, by name.

Standard oncology care is the evidence-based route: surgery, radiotherapy, systemic therapy and clinical trials. The FDA points out that patients can lawfully get investigational drugs, for example by joining clinical trials [source: FDA consumer update].
For symptom relief and quality of life, there are palliative and supportive care, psycho-oncology, and integrative oncology alongside treatment (see 172).
For health anxiety or somatic distress that follows the experience, use established psychological treatments (see Domain II).
The psychotherapist never sells, prescribes or recommends the Hoxsey tonic, its herbs, escharotic pastes or any clinic, and does not advise on stopping or starting any medicine or remedy. Those questions go to the oncologist, GP or pharmacist [synthesis].

Everything in the interventions below is [synthesis] unless a source is given: these are the clinician's own procedures, informed by the harms documented above.

5.1 Asking about alternative cancer treatment, without judgement

Purpose: find out early whether a client or a family member is considering, taking or recovering from Hoxsey-type products or a clinic. Use it at intake with anyone affected by cancer, and again at each change in treatment.
Steps: (1) Make asking routine for all clients affected by cancer. (2) Ask open questions about everything they are taking or considering, including herbs, tonics, salves and overseas clinics. (3) Record names, sources, and who recommended them. (4) Ask whether their doctors know. The FDA and MSK both advise patients to tell providers about all herbs, supplements and home remedies [source: MSK; FDA Q&A]. (5) Do not challenge in the first conversation. Signal that you are curious and safe to tell.
Example language (illustrative): "Many people with cancer look into other treatments, and I'd rather know than not. Is there anything you're taking or thinking about, like herbs, tonics, creams, or a clinic abroad?"
Watch for: secrecy from the medical team, products applied to skin lesions (an urgent risk), people stopping or postponing scheduled treatment, large payments. It is working when the client tells you about use without becoming defensive and agrees to share the information with their doctor.

5.2 Exploring meaning, hope and the explanatory model

Purpose: understand what draws the person: control, hope when prognosis is poor, fear of surgery or side effects, distrust of medicine, identity, family or community loyalty, a persuasive story of persecution [source for the story's appeal: McGill OSS].
Steps: (1) Ask what they have heard and from whom. (2) Ask what they hope it will do and what they fear about standard care. (3) Reflect the values underneath, such as autonomy, wanting to stay "natural", or protecting the body. (4) Summarise without correcting yet.
Example language (illustrative): "It sounds like what matters most is not being cut or burned and feeling you're in charge of your own body. Did I get that right?"
Watch for: fear of a specific treatment that a referral could address (needle phobia, trauma from past surgery, fear of nausea); hopelessness disguised as "choice". Movement shows when the client separates the value (control, gentleness) from the product.

5.3 Autonomy-respecting decision support

Purpose: help an adult with capacity make an informed decision that fits their values, without coercion from the therapist, the family or the seller.
Steps: (1) Ask permission before sharing information. (2) Offer accurate, sourced facts in plain words. For example, MSK states that the regimen "is not a cancer cure" and that some components may be dangerous; regulators shut it down in the US; using alternative medicine alone for curable cancers is linked to higher mortality [source: MSK; FDA; Johnson et al. 2018]. (3) Encourage a dedicated consultation with the oncologist about the real benefits and burdens of each standard option, including declining treatment or choosing palliative care. (4) Help the client prepare questions for that consultation. (5) Respect the final decision of a person with capacity. Keep the relationship open and document it. No published decision aid for this regimen is cited here [uncertain: not verified].
Example language (illustrative): "This is your decision, and I'll keep working with you whatever you choose. Would it help to go through the questions you'd want your oncologist to answer before you decide?"
Watch for: the therapist arguing (which tends to entrench the position), a family member speaking for the client, a seller's deadline ("the package price ends Friday"), and questions about capacity during acute distress or brain involvement. It is working when the client attends the oncology consultation and can state the trade-offs in their own words.

5.4 Coordinating with the treating team

Purpose: make sure the physician, oncology team, palliative team or pharmacist knows about the products, so interactions and toxicity can be checked. MSK lists interactions between potassium iodide and lithium and anticoagulants, and toxicity from licorice, pokeweed and laxative herbs [source: MSK].
Steps: (1) Get written consent for contact. (2) Share only what is needed: the product names, the source, how long they have been used, and any skin product. (3) Ask the team to review interactions and to see the client soon about any skin lesions or burns. (4) Agree who will talk with the client about medical questions (the team, not you).
Example language (illustrative): "Would you be OK with me letting Dr [name]'s team know about the tonic, so they can check it against your other medicines? I won't tell them anything else without asking you."
Watch for: refusal of consent (explore it, document it, and reassess at the next session); any burn, ulcer or worsening wound from a salve, which needs same-day medical review. It is working when the team confirms that they know.

5.5 Grief, regret and self-blame after choosing alternatives

Purpose: support people (or bereaved relatives) who delayed or refused standard treatment and now face progression, disfigurement or death.
Steps: (1) Name the grief and regret without collusion or blame. (2) Separate their responsibility from the deception that was documented (false diagnoses, testimonials, persecution narratives) [source for deception: 198 F.2d 273; McGill OSS]. (3) Work with self-compassion and hindsight bias. (4) For bereaved families, use standard bereavement approaches, and assess for complicated or prolonged grief and guilt. (5) Refer to palliative and bereavement services.
Example language (illustrative): "You chose with the information and hope you had then. The people selling it were very skilled at making it look like a real chance."
Watch for: suicidal ideation linked to guilt or prognosis, which calls for a standard risk assessment; anger directed at the oncology team that blocks care that is still possible. It is working when the client can talk about the decision without collapsing into blame.

5.6 Family conflict

Purpose: reduce the polarisation that arises when relatives either push the regimen or try to force standard care.
Steps: (1) Meet the client alone first, to hear their wishes. (2) In a family session, set ground rules and have each person state their fear and their hope. (3) Bring the shared goal (the patient's wellbeing and wishes) to the front. (4) Direct factual disputes to a joint meeting with the oncologist. (5) Protect the patient's right to decide.
Example language (illustrative): "Everyone here is frightened of losing them. Could each of you say what you're most afraid will happen?"
Watch for: coercion in either direction, financial pressure from relatives who are paying, and children being drawn into taking sides.

5.7 Financial harm

Purpose: address debt, fundraising pressure and shame after paying for packages, travel or mail-order supplies [source for cost structure: McGill OSS; 198 F.2d 273].
Steps: Ask about the costs. Screen for crowdfunding pressure. Refer to financial counselling or a hospital social worker. Inform the client about consumer complaint routes (see 5.9). Work with the shame.
Example language (illustrative): "Can we look at what this has cost you so far, and whether anyone can help you get some of it back or plan from here?"
Watch for: sellers' upsells and repeat orders, and loans from vulnerable relatives.

5.8 Safeguarding

Purpose: protect children and adults at risk who are given these products or kept from medical care.
Steps: (1) Treat a child with cancer being withheld from treatment for a Hoxsey-type regimen, or given pokeweed-containing products or caustic salves, as a safeguarding concern [source for pokeweed deaths in children: MSK]. (2) Follow your local child-protection procedure and consult your safeguarding lead. (3) For a child, talk with the child about their understanding and assent in a way that fits their age, and do not name minors in records shared outside the care team. (4) For an adult at risk who lacks capacity or is being coerced, use adult-safeguarding routes.
Example language (illustrative): "I can see how much you love her and want to protect her. I have to be honest that I'm worried she isn't getting the treatment her doctors recommend, and I need to talk with our safeguarding lead about how to help."
Watch for: missed oncology appointments, visible burns or wounds, and isolation of the family by a group or seller.

5.9 Reporting

Purpose: use the right regulatory route when products, sellers or practitioners are causing harm.
Steps (US): report serious adverse events from products to FDA MedWatch, and general product problems through the FDA problem-reporting page or 1-888-INFO-FDA. The FDA also points to the FTC's cancer treatment scam guidance [source: FDA Q&A]. Licensed professionals who promote such regimens can be reported to their licensing board [synthesis]. Other jurisdictions: report to the national medicines regulator, the advertising regulator and the consumer-protection regulator, and to the professional or licensing board for a regulated practitioner. The UK has specific law on cancer-treatment advertising [uncertain: not verified].
Example language (illustrative): "Would you be willing for us to report the seller? It won't change your care here, and it might protect someone else."
Watch for: confidentiality limits (get consent unless a safeguarding duty overrides it), and document what you reported and when.

5.10 Ethics and conflicts of interest

Do not sell or recommend products, clinics or courses. Do not take referral fees. Do not collect testimonials. Stay within your competence on medical matters. Professional ethics codes cover these duties; specific code text is [uncertain: not verified; synthesis].

5.11 Problems and responses

Client insists the tonic is working. Ask how they and their doctors would know (scans, biopsy). Agree to keep both in view [synthesis; principle from 198 F.2d 273].
Client stops attending after you raise concerns. Send a brief, warm, non-judgemental note keeping the door open [synthesis].
Overwhelm at the news of progression. Use grounding and slow the pace. Coordinate with palliative care [synthesis].
Therapist's own anger at the sellers. Seek supervision. Keep the focus on the client, not on winning the argument [synthesis].

Sources

← Previous · XII-152Laetrile (vitamin B17)Next · XII-154 →Essiac